IBI-324 / Innovent Biologics, Ollin Biosciences - LARVOL DELTA

Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration (GlobeNewswire) - "OLN324 demonstrated both faster and greater retinal drying versus faricimab in patients with DME, with OLN324 4mg treated patients experiencing mean improvements in retinal drying that were ~75% greater than faricimab at Week 1 (-79 µm vs. -45 µm mean change in central subfield thickness or CST, respectively), and ~50% greater at Week 12 (-180 µm vs. -121 µm), measured using optical coherence tomography (OCT)....Ollin plans to discuss the JADE study and additional pipeline and corporate progress during its upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference, on Tuesday, January 13, 2026. Full results of the study will be presented for the first time at the upcoming Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026."

P1 data • Pipeline update • Diabetic Macular Edema • Wet Age-related Macular Degeneration

Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in 2026 (Businesswire)

New P3 trial • Diabetic Macular Edema • Wet Age-related Macular Degeneration

Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema. (PubMed, BMJ Open Ophthalmol) - P1 | "IBI324 was well tolerated with evidence of functional and anatomical improvement in patients with DME."

Journal • P1 data • Cataract • Conjunctivitis • Diabetic Macular Edema • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology

Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) (PRNewswire-Asia) - "Ollin has completed enrollment of over 150 patients with wAMD or DME in the JADE study, a randomized, U.S.-based, Phase 1b proof-of-concept clinical trial designed to evaluate OLN324 versus faricimab for potential areas of anatomic and durability differentiation. Topline results from the study are expected in the first quarter of 2026."

Enrollment closed • P1 data • Diabetic Macular Edema • Wet Age-related Macular Degeneration

IBI324/OLN324: A clinical-stage, small-format, higher-potency, high molar dose bispecific VEGF/Ang-2 inhibitor (ARVO 2025) - "OLN324 (IBI324) is a novel, small-format (~41 kDa) bispecific antibody targeting VEGF and Ang-2 with substantially higher potency and molar dose than faricimab, features giving it the potential for better clinical efficacy and durability. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Ocular Inflammation • Ophthalmology • Wet Age-related Macular Degeneration

A Phase 1 Study of Anti-VEGF/Anti-Angiopoietin 2 Bispecific Antibody IBI324 for DME (AAO 2023) - "Furthermore, improvements in anatomical parameters were also observed after IBI324 treatment. Conclusion IBI324 was well tolerated and safe, with a preliminary visual and anatomical efficacy signal."

P1 data • Diabetic Macular Edema • Ophthalmology

Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023 (PRNewswire) - P1 | N=24 | NCT05489718 | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | "Innovent Biologics...presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting....This is a Phase 1 clinical study evaluating the safety, tolerability, and efficacy of IBI324 in the treatment of DME....In terms of safety, 4 mg/eye was the maximum tolerated dose in the study. No ocular serious adverse events (SAE), intraocular inflammation, or dose-limiting toxicities (DLTs) occurred during the study. In the SAD phase, BCVA and CST improved from baseline to Day 42 post-dose in every IBI324 dose group. In the MAD phase, BCVA improved from baseline by 6.7±5.4 letters and 7.7±4.7 letters in the IBI324 2 mg and 4 mg groups, respectively, by 4 weeks after the third dose (Day 84)."

P1 data • Diabetic Macular Edema

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Oct 2023 ➔ Jun 2023

Trial completion • Trial completion date • Diabetic Macular Edema • Ophthalmology

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Diabetic Macular Edema • Ophthalmology